Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio shares are trading sharply higher Monday afternoon. The FDA granted Orphan Drug Designation to its cell therapy, MB-101.

Get today's Mustang Bio stock news. We cover the latest Mustang Bio headlines and breaking news impacting Mustang Bio stock performance.

Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...

Mustang Bio, Inc. Common Stock (MBIO) Analyst Research This feature is currently unavailable; we are sorry for the inconvenience to you.

Trump announced a 35% tariff on Canadian goods late Thursday on Truth Social, claiming Canada had "financially retaliated" to earlier duties. A White House official said, however, that many ...